Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Biosimilars Market is encountering a development at an exponential rate. By and by around 700 biologics are gaining ground in the examination pipelines of almost 250 Biopharma organizations. Biosimilars have just begun up setting the future medication advancement in the domain of Oncology, Dermatology, Urology etc.


  • Track 1-1 Biosimilars for Cancer Treatment
  • Track 1-2 Biosimilars for Immune Disorder Treatment
  • Track 1-3 Monoclonal Antibody Biosimilars
  • Track 1-4 Erythropoietin Biosimilars

Expository, preclinical and clinical pharmacokinetic/pharmacodynamic examines show that the dynamic substance in the Biosimilar solution coordinates the reference prescription. Last affirmation of Biosimilarity requires a clinical Phase III corroborative wellbeing and viability think about in a touchy sign. Both methodologies furnish a similar level of certainty with respect to wellbeing and adequacy of the natural drug.


  • Track 2-1 Approval Process for Biosimilar Products
  • Track 2-2 Integrated Approach for Biosimilar development
  • Track 2-3 Clinical Trial Design
  • Track 2-4 New Trends in Delivery Systems
  • Track 2-5 Improving the Drug Performance

Biological products are the fastest-growing class of therapeutic products in the world. When patients are prescribed a biological product, biosimilar and interchangeable products can offer additional treatment options, potentially lowering health care costs.


  • Track 3-1 Biological Products
  • Track 3-2 Biosimilar Products
  • Track 3-3 Approval Standards for Interchangeable Products
  • Track 3-4 Enhancing the Treatment Procedures

Monoclonal antibodies (mAbs) are natural specialists that are broadly used to treat malignancies including non-Hodgkin's lymphomas and ceaseless lymphocytic leukaemia. They are compelling however costly. The licenses for some, mAbs are lapsing, so biosimilar solutions, which contain an adaptation of the dynamic element of the first medication, are being produced. 

  • Track 4-1 Monoclonal Antibodies in Oncology
  • Track 4-2 Lymphatic Disorder Treatment
  • Track 4-3 Rheumatoid Arthritis Treatment
  • Track 4-4 Guidelines for Monoclonal Antibody Production

This track plates about the non-specific medications effect on worldwide biosimilar showcase, Cost and hazard administration, Adopting creative systems, for example, chance sharing plan, European market for biosimilars. The worldwide market situation with the dispatch of first biosimilar in the market estimates some radical changes. This track will view such key concerns which are seen by the worldwide pharma showcase and that are thinking of the consequent dispatch of alternate biosimilars and biologics. Despite these rising offices, bio therapeutic designers are most agreeable off-shoring to set up business sectors

  • Track 5-1 Biosimilar Multimodel Techniques
  • Track 5-2 Biosimilar Electrophoresis
  • Track 5-3 Biosimilar Formulation
  • Track 5-4Supply Chain Challenges Before Biosimilars
  • Track 5-5 Biosimilar GMP Protein Analysis

Biosimilars is a biologic therapeutic item which is duplicate of a unique item that is made by an alternate organization. Biosimilars are formally affirmed creative adaptations of unique items, and can be made when the first item's patent terminates. Reference to the trailblazer item is a necessary segment of the endorsement. This session likewise discovers put for all the biosimilar exhibitors related with the field of biosimilar and biologics.


  • Track 6-1 Biosimilars in Global Market
  • Track 6-2 Economic Aspects Towards Biosimilars
  • Track 6-3 Cost and Risk Management
  • Track 6-4 Global Impact of Biosimilars over Generics

This track discusses about the new techniques and innovation of biosimilar drugs that play a major role in pharmaceutical industry in reducing the cost of manufacturing and lowering the risk of side effects and maintaining the quality.

  • Track 7-1 Purpose and Principles of GMP
  • Track 7-2 R&D and way to Innovation of New Medicines
  • Track 7-3 Pharmaceutical Process Validation
  • Track 7-4 Regulatory Requirements

Bioequivalence centres around the equality of arrival of the dynamic pharmaceutical fixing from the pharmaceutical item and its resulting assimilation into the fundamental flow. This session has most extreme significance in setting to the way that lone an appropriately bioequivalent sedate competitor that adjusts the outcomes in all regards to the first authorized item can be called as biosimilar tranquilize.

  • Track 8-1 Strategies for the Bioequivalence Assessment of Topical Dosage Forms
  • Track 8-2 Evaluation of Hghly Variable Drugs and Drug Products
  • Track 8-3 Bioequivalence approaches for Transdermal Dosage Forms
  • Track 8-4 Bioequivalence Assessment of Respiratory Dosage Form

The Brexit impact on Biosimilars has a tendency to be negative. In addition to the fact that it would be a noteworthy mishap towards endorsement and dispatch of biosimilars to the market yet additionally it would be deterrent towards the cost cutting methodology taken up by NHS. With Britain being among chief clinical trial focuses is possessed to see a reduction in the ability of the makers and specialists to complete any further trials in Britain.

  • Track 9-1 Brexit pros and cons to European Pharma Market
  • Track 9-2 Post Brexit Changes in Biosimilar Regulation in UK
  • Track 9-3 Fate of Biosimilars Clinical Trials in UK

This track incorporates Clinical trials on significant maladies Risk administration, and quality issues, Case thinks about, and clinical models, Transgenic creatures, Targeted cell line advancement, Clinical biosimilar tracks.docx PK/PD examines, Toxicological investigations and Aspects of genotoxicity tests. Clinical trials are planned in stages I-IV in order to get a reasonable photo of the medication applicant in regard to its pharmacokinetics and pharmacodynamics parameters.

  • Track 10-1 Aspects of Genotoxicity Tests
  • Track 10-2 Biosimilars Clinical Studies
  • Track 10-3 Case Studies and Clinical Models
  • Track 10-4 Toxicological Studies
  • Track 10-5 Transgenic Animals

This session of the Biosimilars 2018 will investigate the future and FDA activities that have just been reported to incorporate upgraded following and follow-up of post showcasing reconnaissance issues, arranged enhancements in AERS, and pilots of new post advertise sedate observing procedures and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmacoepidemiology are the focuses that might be laid accentuation in this session.

  • Track 11-1 Role of Pharma Industries in the Improvement of Pharmacovigilance System
  • Track 11-2 Current Problems in Biosimilar Pharmacovigilance
  • Track 11-3 Detection and Evaluation of Drug Safety Signals
  • Track 11-4 Adverse Drug Reactions with Pharmaceutical Products
  • Track 11-5 Pharmacoepidemiology and GMP

Floor covering Delivery Companies and Market session is starting to change for little, medium, and huge scale pharmaceutical Co, biopharmaceutical Manufacturing and Industries, non-specific medications organizations, contract sedate conveyance organizations which can show from improvement to assembling. Tending to these insecurities is an extraordinary test, on account of the many-sided quality of the Clinical bio therapeutics themselves


  • Track 12-1 New Approaches to Enhance Drug Performance.
  • Track 12-2 Drug Delivery Companies and Markets
  • Track 12-3 Drug Delivery Companies and Market Strategies
  • Track 12-4 Drug Delivery Technologies

Unique in relation to completely integrated pharmaceuticals, they incorporate immunizations, blood, blood segments, allergenics, substantial cells, quality treatments, tissues, recombinant helpful protein, and living cells utilized as a part of cell treatment. Biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live cells or tissues.

  • Track 13-1 Biopharmaceutical Research
  • Track 13-2 Recombinant Protein Expression
  • Track 13-3 Monoclonal Antibodies

The EU represents 22 percent of the market's business esteem and 14 percent of its esteem development. Conversely, developing markets speak to only a fragment of the business pie, with 7.5 percent share. Consequently, biologics showcase development is still to a great extent driven by develop markets. The worldwide biologics advertise had come to $170 billion in deals an incentive in 2012, representing 18 percent of the general market.

  • Track 14-1 Biosimilars Europe
  • Track 14-2 Rise in Biosimilar Use
  • Track 14-3 Contribution of Biosimilars in Global Market

Expository information submitted ought to be to such an extent that firm conclusions on the physicochemical and organic comparability between the reference restorative item and the biosimilar can be made.

  • Track 15-1 GMP Guidelines
  • Track 15-2 Demonstration Equivalence in Contrast to Non-inferiority
  • Track 15-3 Importance of Similarity on the Quality Level

This track describes about the use of biosimilars in in vivo studies and their Importance in estimating their therapeutic importance and activity. In September 2013 the first biosimilar mAb, infliximab, was authorised in Europe.

  • Track 16-1 Non-clinical in Vivo Studies
  • Track 16-2 Development of Unmarked Biosimilars
  • Track 16-3 Minimisation of Unnecessary Use of Animals
  • Track 16-4 Toxicology Studies

The worldwide erythropoietin biosimilars medicate showcase has been developing quickly in the previous decade, principally because of the patent expiry of significant erythropoietin biologic medication in European market

  • Track 17-1 Growth of Erythropoietin Biosimilar Drug Market
  • Track 17-2 Erythropoietin Stimulating Agents
  • Track 17-3 Erythropoietin Biosimilars for Anaemia Treatment
  • Track 17-4 Cloning of Genes for Erythropoietin Biosimilars

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the therapeutic management of inflammatory rheumatic diseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.

  • Track 18-1 Reasons of Switching
  • Track 18-2 Immunogenicity
  • Track 18-3 Switching of bDMARD to its Biosimilars
  • Track 18-4 Switches in Clinical Trails

This track discusses means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein or analogous product, or arsphenamine or derivative of arsphenamine, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Track 19-1 Biosimilar Biological Products
  • Track 19-2 Conceptual Development of Biosimilars
  • Track 19-3 Drug Designing
  • Track 19-4 Safety and Efficacy of Biological Biosimilars

Not at all like non specific meds in which the dynamic fixings are indistinguishable to the reference small– atom medicate, biosimilars won't be indistinguishable to the reference biologics.

  • Track 20-1Advanced Clinical Effects
  • Track 20-2New Pathways for Development
  • Track 20-3Advancement in Drug Delivery System
  • Track 20-4Minimisation of Side Effects